Final Programme - iuphar

More documents

Recommendations

Info

FC10 Drugs for half the world: Paediatric clinical pharmacology Wed 09:30 FC10.1 Innovative methodological approaches in drug development in children Wed 14:30 FC10.2 WHO and medicines in developing countries Thu 09:30 FC10.3 Formulation issues Thu 14:30 FC10.4 Pain in children Fri 09:30 FC10.5 Recent advance in paediatric clinical pharmacology FC11 G protein-coupled 7TM receptors: From molecular to physiological function Wed 09:30 FC11.1 7TM receptor structure Wed 14:30 FC11.2 7TM receptors: Activation, inactivation and allosteric modulation Thu 09:30 FC11.3 7TM receptors: Scaffolding and signalling mechanisms Thu 14:30 FC11.4 7TM receptors: Genetic mouse models and disease Fri 09:30 FC11.5 7TM receptors: Drug discovery and new physiological functions FC12 Ion channelopathies: New windows on complex disease and therapy Wed 09:30 FC12.1 Ion channelopathies in the brain: Inherited epilepsy and migraine Wed 14:30 FC12.2 Ion channelopathies of peripheral nerve and muscle: Inherited pain and periodic paralysis Thu 09.30 FC12.3 Ion channelopathies in the cardiovascular system: Inherited arrhythmia and hypertension Thu 14:30 FC12.4 Ion channelopathies in endocrine systems Fri 09:30 FC12.5 Ion channelopathies in lymphocytes: Severe combined immunodeficiency and store-operated calcium channels FC13 Maximising benefits and minimizing harms from drugs Wed 09:30 FC13.1 Drug safety: The epidemiology Wed 14:30 FC13.2 Drug metabolism and drug toxicity Thu 09:30 FC13.3 Pharmacogenomics and adverse drug reactions Thu 14:30 FC13.4 New technologies – will they help in developing safer drugs Fri 09:30 FC13.5 New insights in the genetics of drug metabolism and action FC14 Addiction and doping: Neurobiological and clinical basis of emerging treatments Wed 09:30 FC14.1 Pharmacological treatment of opiate dependence – much achieved, much left to do Wed 14:30 FC14.2 Pharmacological treatments of alcohol dependence – illusion or opportunity? Thu 09:30 FC14.3 Craving and relapse to drug seeking: Lessons from animal models and human brain imaging Thu 14:30 FC14.4 The role of stress in the addictive process Fri 09:30 FC14.5 Doping – an underestimated problem with many unknowns FC15 Endothelium in health and disease Wed 14:30 FC15.1 Nitric oxide and oxidative stress Thu 09:30 FC15.2 Endothelium-dependent hyperpolarization Thu 14:30 FC15.3 Endothelium-mediated control of vascular tone Fri 09:30 FC15.4 Drug development and novet therapeutic targets and approaches FC16 Natural products: Past and future? Wed 09:30 FC16.1 Cardioprotection by natural products Wed 14:30 FC16.2 Products derived from one single plant with convincing pharmacological data in explaining their mechanism of action Thu 09:30 FC16.3 Multiple plant products: A matter of synergy Thu 14:30 FC16.4 East meets west: From prevention to therapy Fri 09:30 FC16.5 Globalization of natural/traditional products 20 <strong>Programme</strong> outline
FC17 New approaches and targets in psychiatry Wed 09:30 FC17.1 The pathophysiological basis for psychosis Wed 14:30 FC17.2 Exploring new targets in schizophrenia using translation science Thu 09:30 FC17.3 Clinical aspects of treatment with antipsychotics Thu 14:30 FC17.4 Exploring new targets in affective disorders using translational science Fri 09:30 FC17.5 New pharmacological approaches for treatment of stress induced mood disorders FC18 Nuclear receptor targets for treatment of diseases Wed 14:30 FC18.1 Nuclear receptors and metabolic control Thu 09:30 FC18.2 Nuclear receptors, vascular function and Inflammation Thu 14:30 FC18.3 Nuclear receptors in the CNS Fri 09:30 FC18.4 The molecular basis of NR pharmacology Sponsored symposium Mon 12:45 SS01 Benefit/risk ratio for antipsychotics: Pharmacovigilance evidence and regulatory commitments Sponsored by AstraZeneca Italy Workshops W01 Symposium: Pharmacology of adrenoceptors: Eighth satellite meeting Sun 09:45 W01.1 Part I – Molecular structure Sun 12:45 W01.2 Part II – Pharmacology Sun 15:00 W01.3 Part III – Therapeutics W02 Symposium: Advances in GI pharmacology Sun 12:45 W02.1 Part I – Gastrointestinal nutrient chemosensing and the gut-brain axis Mon 9:30 W02.2 Part II – From functional to structural disease targets Mon 12:45 W02.3 Part III – From functional to structural disease targets, continued Sun 12:45 W03 Workshop: Targeting TRP channels for pain relief (and more) W04 Symposium: Antioxidants as therapeutic targets Sun 12:45 W04.1 Part I – Systems biology Tue 12:45 W04.2 Part II – Cardiovascular health Wed 12:45 W04.3 Part III – Antioxidants as therapeutic targets Mon 12:45 W05 Workshop: Clinical trials across Europe and the role of pharmacologists Mon 12:45 W06 Workshop: Effect of disease on cytochrome p450 and membrane transporters Mon 12:45 W07 Workshop: Circadian clocks for drug development and therapeutics Mon 12:45 W08 Workshop: Identifying targets for treating vascular diseases associated to metabolic disorders Mon 12:45 W09 Workshop: Blood cells and cytokines as emerging targets for cardiovascular pharmacology Mon 12:45 W10 Workshop: Innovative Medicines Initiative: A new approach to education & training in medicines research in Europe Mon 12:45 W11 Workshop: New opportunities in the pharmacology of neuro-immune interactions Tue 12:45 W12 Workshop: Experimental pain methods in development and validation of analgesics <strong>Programme</strong> outline 21
Page 1: of basic and clinical pharmacology
Page 4 and 5: Congress patron 2 HRH Crown Princes
Page 6 and 7: Congress President Kim Brøsen Secr
Page 8 and 9: General information Registration &
Page 10 and 11: Banks, currency & credit cards The
Page 12 and 13: Information to presenters ■ The a
Page 14 and 15: Hotel Bella Center Copenhagen Groun
Page 16 and 17: Programme at a glance Time Hall A2
Page 18 and 19: 16 General events General events Op
Page 20 and 21: Programme outline Plenary lectures
Page 24 and 25: Tue 12:45 W13 Workshop: Novel perip
Page 26 and 27: W01 Pharmacology of adrenoceptors:
Page 28 and 29: W02 Symposium on advances in GI pha
Page 30 and 31: W04 Symposium: Antioxidants as ther
Page 32 and 33: Plenary lectures PL01 Plenary lectu
Page 34 and 35: FC02 Transmembrane transport: Persp
Page 36 and 37: FC04 Pharmacoepidemiology, current
Page 38 and 39: FC06 The heart gone wrong: Stabiliz
Page 40 and 41: FC09 Inflammation and immunopharmac
Page 42 and 43: W02 Symposium on advances in GI pha
Page 44 and 45: SS01 Sponsored symposium Sponsored
Page 46 and 47: W06 Workshop. Effect of disease on
Page 48 and 49: W08 Workshop. Identifying targets f
Page 50 and 51: W10 Workshop. Innovative Medicines
Page 52 and 53: FC01 Clinical pharmacology in the e
Page 54 and 55: FC03 Ion channels in analgesia and
Page 56 and 57: FC05 Translational science in the m
Page 58 and 59: FC06 The heart gone wrong: Stabiliz
Page 60 and 61: FC08 Development in the treatment o
Page 62 and 63: Plenary lectures PL04 Plenary lectu
Page 64 and 65: FC01 Clinical pharmacology in the e
Page 66 and 67: FC03 Ion channels in analgesia and
Page 68 and 69: FC05 Translational science in the m
Page 70 and 71: FC07 Simulation and data modelling
Page 72 and 73:
FC09 Inflammation and immunopharmac
Page 74 and 75:
W12 Workshop. Experimental pain met
Page 76 and 77:
W14 Workshop. Translating the human
Page 78 and 79:
W15 Workshop. The IUPHAR initiative
Page 80 and 81:
W17 Workshop. Standards for PhD Edu
Page 82 and 83:
W19 Workshop. Influence of degenera
Page 84 and 85:
FC02 Transmembrane transport: Persp
Page 86 and 87:
FC04 Pharmacoepidemiology, current
Page 88 and 89:
FC06 The heart gone wrong: Stabiliz
Page 90 and 91:
FC08 Development in the treatment o
Page 92 and 93:
PL10 ASPET Plenary Lecture Chair: T
Page 94 and 95:
FC10 Drugs for half the world: Paed
Page 96 and 97:
FC12 Ion channelopathies: New windo
Page 98 and 99:
FC14 Addiction and doping: Neurobio
Page 100 and 101:
FC17 New approaches and targets in
Page 102 and 103:
W04 Symposium: Antioxidants as ther
Page 104 and 105:
W21 Workshop. Inflammation - here,
Page 106 and 107:
W23 Workshop. Applying pharmacogeno
Page 108 and 109:
W25 Workshop. High science in the l
Page 110 and 111:
W27 Workshop. Approaches to medicin
Page 112 and 113:
FC11 G protein-coupled 7TM receptor
Page 114 and 115:
FC13 Maximising benefits and minimi
Page 116 and 117:
FC15 Endothelium in Health and dise
Page 118 and 119:
Page 120 and 121:
FC18 Nuclear receptor targets for t
Page 122 and 123:
PL16 Plenary Lecture Supported by a
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
FC15 Endothelium in Health and dise
Page 130 and 131:
Page 132 and 133:
W28 Workshop. The Boehringer-Ingelh
Page 134 and 135:
W30 Workshop. Is eNOS still a valid
Page 136 and 137:
W32 Workshop. The good, the bad and
Page 138 and 139:
W34 Workshop. State-of-the-art of b
Page 140 and 141:
FC10 Drugs for half the world: Pedi
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
FC16 Natural products: Past and fut
Page 148 and 149:
Page 150 and 151:
PL22 Plenary Lecture Chair: Zhi-Bin
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
FC15 Endothelium in health and dise
Page 158 and 159:
Page 160 and 161:
158
Page 162 and 163:
FC01 Clinical pharmacology in the e
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
FC03 Ion channels in analgesia and
Page 170 and 171:
W12 Experimental pain methods in de
Page 172 and 173:
Page 174 and 175:
FC05 Translational science in the m
Page 176 and 177:
Page 178 and 179:
FC06 The heart gone wrong; stabiliz
Page 180 and 181:
FC07 Simulation and data modelling
Page 182 and 183:
FC08 Developments in the treatment
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
W03 Targeting TRP channels for pain
Page 196 and 197:
W19 Influence of degeneration and r
Page 198 and 199:
W19 Influence of degeneration and r
Page 200 and 201:
W20 Pharmacology education for a su
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
FC06 The heart gone wrong; stabiliz
Page 216 and 217:
FC07 Simulation and data modelling
Page 218 and 219:
FC08 Developments in the treatment
Page 220 and 221:
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
FC19 General session Tue 361 Analge
Page 232 and 233:
FC19 General session - Biologics Tu
Page 234 and 235:
FC19 General session - Haematology
Page 236 and 237:
FC19 General session - oncology Tue
Page 238 and 239:
FC19 General session - oncology Tue
Page 240 and 241:
FC19 General session - Toxicology T
Page 242 and 243:
W02 Symposium on advances in GI pha
Page 244 and 245:
W11 New opportunities in the pharma
Page 246 and 247:
W23 Applying pharmacogenomics (PGX)
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
Page 256 and 257:
Page 258 and 259:
Page 260 and 261:
Page 262 and 263:
Page 264 and 265:
Page 266 and 267:
Page 268 and 269:
W30 Is eNOS Still a valid therapeut
Page 270 and 271:
Page 272 and 273:
Page 274 and 275:
Page 276 and 277:
Page 278 and 279:
Page 280 and 281:
W34 State-of-the-art of basic and c
Page 282 and 283:
Page 284 and 285:
Page 286 and 287:
Page 288 and 289:
Page 290 and 291:
Page 292 and 293:
Page 294 and 295:
W29 New horizons in therapeutic dru
Page 296 and 297:
Page 298 and 299:
Page 300 and 301:
Page 302 and 303:
Page 304 and 305:
Page 306 and 307:
Page 308 and 309:
Page 310 and 311:
Page 312 and 313:
Page 314 and 315:
Page 316 and 317:
314 Index Name Paper ref. Name Pape
Page 318 and 319:
Page 320 and 321:
Page 322 and 323:
Page 324 and 325:
Page 326 and 327:
Page 328 and 329:
Page 330 and 331:
Page 332 and 333:
Page 334 and 335:
Page 336 and 337:
Page 338 and 339:
Page 340 and 341:
Page 342 and 343:
Page 344 and 345:
Page 346 and 347:
Page 348 and 349:
Page 350 and 351:
Page 352 and 353:
Page 354 and 355:
Page 356 and 357:
Page 358 and 359:
Page 360 and 361:
Page 362 and 363:
Page 364 and 365:
Page 366 and 367:
Page 368 and 369:
Page 370 and 371:
Page 372 and 373:
Page 374 and 375:
Page 376 and 377:
Page 378 and 379:
Page 380 and 381:
Page 382 and 383:
Page 384 and 385:
382 Notes Notes
Page 386:
Final Programme printed in Singapor
show all

Final Programme - iuphar

Create successful ePaper yourself

Delete template?

Save as template?